stride semaglutide (#ozempic / #wegovy) increased walking distance in patients with symptomatic peripheral artery disease and type 2 #diabetes.Peripheral artery disease is a debilitating atherosclerotic ACC 25: semaglutide improves PAD

SKU: 77245493435

Pay in 4 interest-free payments of $6.96 Learn more

Live Spec

ACC 25: semaglutide improves PAD patients with T2D Semaglutide for PAD in Diabetes: What the STRIDE Trial Just Revealed Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double blind, randomised, placebo controlled trial The Lancet Post hoc analysis of STRIDE found semaglutide had a beneficial effect on functional outcomes in people with peripheral artery disease and type 2 diabetes regardless of type 2 diabetes characteristics. @ADA_Pubs Read ACC 25 Late Breaking Discussion: STRIDE: Semaglutide for Functional Capacity in Pts with T2D and PAD Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial Joakim Nordanstig

Store: vanlokventuinen.nl · Domain: vanlokventuinen.nl